I Ravelingien Selected Research

C-Reactive Protein

1/2015

Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

I Ravelingien Research Topics

Disease

2	Rheumatic Diseases (Rheumatism) 01/2015 - 07/2009
1	Rheumatoid Arthritis 01/2015
1	Joint Diseases (Joint Disease) 01/2015

Drug/Important Bio-Agent (IBA)

1	ametantrone (HAQ)IBA 01/2015
1	Leflunomide (Arava)FDA LinkGeneric 01/2015
1	C-Reactive ProteinIBA 01/2015
1	GlucocorticoidsIBA 01/2015
1	Methotrexate (Mexate)FDA LinkGeneric 01/2015
1	Prednisone (Sone)FDA LinkGeneric 01/2015
1	W 7 (W7)IBA 01/2015
1	Antinuclear AntibodiesIBA 07/2009

Therapy/Procedure

1	Remission Induction 01/2015
1	Therapeutics 01/2015